Metraipolis › archive › dc_52145e84e2f0

Finite-Boundary Reduction and Exact Verification of Strong Familywise Error in Active-Count-Coupled Multi-Arm Efficacy-Toxicity Monitoring — arXiv:2609.06886

Source
arXiv (en)
Original
https://arxiv.org/abs/2609.06886
License (as archived)
CC0-1.0
Archived
2026-10-16T14:09:45.168Z
SHA-256 of the archived text
4f5797874b6847bed572bbe402a1ab5a6b110aca12820b44238f007dbc1c2cb4
Stable URL of this page
https://metraipolis.com/documento/dc_52145e84e2f0

How to cite

Finite-Boundary Reduction and Exact Verification of Strong Familywise Error in Active-Count-Coupled Multi-Arm Efficacy-Toxicity Monitoring — arXiv:2609.06886 — arXiv (en), https://arxiv.org/abs/2609.06886 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_52145e84e2f0 (Metraipolis archive dc_52145e84e2f0, sha256 4f5797874b6847bed572bbe402a1ab5a6b110aca12820b44238f007dbc1c2cb4)
BibTeX
@misc{dc52145e84e2f0,
  title = {Finite-Boundary Reduction and Exact Verification of Strong Familywise Error in Active-Count-Coupled Multi-Arm Efficacy-Toxicity Monitoring — arXiv:2609.06886},
  howpublished = {arXiv (en)},
  url = {https://arxiv.org/abs/2609.06886},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_52145e84e2f0; sha256 4f5797874b6847bed572bbe402a1ab5a6b110aca12820b44238f007dbc1c2cb4},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2609.06886. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Randomized dose-optimization trials may screen several candidate doses using binary efficacy and toxicity outcomes. A dose is inadmissible if efficacy is insufficient or toxicity is excessive, so each dose-specific null hypothesis is a union region and strong familywise error control must hold across arbitrary mixtures of inadmissible and promising doses. We study exact verification of multistage monitoring rules in which armwise decisions may be coupled through the number of active arms remaining at each interim analysis. For uncoupled rules, we derive an exact product representation and show that a complete-null boundary configuration is least favourable. Under active-count coupling, this factorization no longer holds because a promising dose can remain active and alter future boundaries for null doses. Assuming independent sampling across arms, prespecified per-dose analysis schedules, analysis timing not driven by the observed efficacy or toxicity outcomes, arm-specific monitoring statistics, and stagewise monotonicity, we establish an exact finite-boundary characterization without parametric restrictions on the within-arm joint efficacy-toxicity distribution. Each dose need only be evaluated at an efficacy-null boundary, a toxicity-null boundary, or a maximally favourable alternative. A deterministic finite-state recursion then verifies a fixed decision table without Monte Carlo error. Numerical studies confirmed the prespecified strong familywise error control and showed that active-count coupling can shift the least-favourable configuration away from the complete null while improving joint retention of multiple promising doses. A published randomized dose-ranging trial was used as a clinical illustration of how the framework could be prospectively implemented. The framework separates monitoring-rule construction from rigorous error verification.

Tema degli esploratori: statistica e scienza dei dati (retro-catalogo arXiv: annunci del 2026-09-09 in stat.ME).
Categorie arXiv: Methodology (stat.ME).
Pagina del lavoro: https://arxiv.org/abs/2609.06886 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina.
Letto il 2026-10-16T13:59:27.870Z dalla pagina https://arxiv.org/catchup/stat.ME/2026-09-09?abs=True (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).